OBJECTIVE: To calculate conditional survival estimates for patients with pancreatic adenocarcinoma. DESIGN: We constructed separate multivariate survival models adjusted for 7 clinicopathologic factors for patients who did and did not undergo radical surgical resection. PARTICIPANTS: Patients with pancreatic adenocarcinoma diagnosed between 1988 and 2005 included in the Surveillance Epidemiology End Results cancer registry. MAIN OUTCOME MEASURE: Internet browser-based calculator to compute personalized survival estimates. RESULTS: Conditional survival probabilities increased over time for all patients with pancreatic cancer regardless of patient characteristics, disease stage, or treatment. For patients with resected stage I, II, or III disease, 3-year conditional cancer-specific survival increased from 38% to 70%, 19% to 54%, and 8% to 39%, respectively, over the 3 years following diagnosis. The relative improvement in survival over time was larger for patients with advanced disease. A customizable, Internet browser-based clinical calculator was implemented that may be used to compute in real time personalized conditional survival estimates based on an individual's unique clinicopathologic profile. CONCLUSIONS: Conditional survival estimates provide a more accurate--and typically more optimistic--assessment of prognosis for patients with pancreatic cancer than traditional survival estimates that apply only at the initial diagnosis.
OBJECTIVE: To calculate conditional survival estimates for patients with pancreatic adenocarcinoma. DESIGN: We constructed separate multivariate survival models adjusted for 7 clinicopathologic factors for patients who did and did not undergo radical surgical resection. PARTICIPANTS: Patients with pancreatic adenocarcinoma diagnosed between 1988 and 2005 included in the Surveillance Epidemiology End Results cancer registry. MAIN OUTCOME MEASURE: Internet browser-based calculator to compute personalized survival estimates. RESULTS: Conditional survival probabilities increased over time for all patients with pancreatic cancer regardless of patient characteristics, disease stage, or treatment. For patients with resected stage I, II, or III disease, 3-year conditional cancer-specific survival increased from 38% to 70%, 19% to 54%, and 8% to 39%, respectively, over the 3 years following diagnosis. The relative improvement in survival over time was larger for patients with advanced disease. A customizable, Internet browser-based clinical calculator was implemented that may be used to compute in real time personalized conditional survival estimates based on an individual's unique clinicopathologic profile. CONCLUSIONS: Conditional survival estimates provide a more accurate--and typically more optimistic--assessment of prognosis for patients with pancreatic cancer than traditional survival estimates that apply only at the initial diagnosis.
Authors: Samuel J Wang; Amanda R Wissel; Join Y Luh; C David Fuller; Jayashree Kalpathy-Cramer; Charles R Thomas Journal: Ann Surg Oncol Date: 2011-01-05 Impact factor: 5.344
Authors: H A Burris; M J Moore; J Andersen; M R Green; M L Rothenberg; M R Modiano; M C Cripps; R K Portenoy; A M Storniolo; P Tarassoff; R Nelson; F A Dorr; C D Stephens; D D Von Hoff Journal: J Clin Oncol Date: 1997-06 Impact factor: 44.544
Authors: Taylor S Riall; John L Cameron; Keith D Lillemoe; Jordan M Winter; Kurtis A Campbell; Ralph H Hruban; David Chang; Charles J Yeo Journal: Surgery Date: 2006-08-28 Impact factor: 3.982
Authors: John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Yezaz A Ghouri; Somashekar G Krishna; Uma R Kundu; Manoop S Bhutani; Manoop S Butani; Jeffrey H Lee; William A Ross Journal: Dig Dis Sci Date: 2015-01-14 Impact factor: 3.199
Authors: David Luyimbazi; Rebecca A Nelson; Audrey H Choi; Lily Li; Joseph Chao; Virginia Sun; John B Hamner; Joseph Kim Journal: J Gastrointest Surg Date: 2014-11-25 Impact factor: 3.452
Authors: Theodoros Michelakos; Yurie Sekigami; Filippos Kontos; Carlos Fernández-Del Castillo; Motaz Qadan; Vikram Deshpande; David T Ting; Jeffrey W Clark; Colin D Weekes; Aparna Parikh; David P Ryan; Jennifer Y Wo; Theodore S Hong; Jill N Allen; Onofrio Catalano; Andrew L Warshaw; Keith D Lillemoe; Cristina R Ferrone Journal: J Gastrointest Surg Date: 2021-01-26 Impact factor: 3.452
Authors: Qinyu Chen; Daniel R Cherry; Vinit Nalawade; Edmund M Qiao; Abhishek Kumar; Andrew M Lowy; Daniel R Simpson; James D Murphy Journal: JCO Clin Cancer Inform Date: 2021-03
Authors: John Bliton; Michael Parides; Peter Muscarella; John C McAuliffe; Katia Papalezova; Haejin In Journal: J Surg Res Date: 2020-12-09 Impact factor: 2.192